Summary & Overview
HCPCS Level II J0614: Injection, treosulfan, 50 mg
HCPCS Level II code J0614 designates the injection of treosulfan, 50 mg — an antineoplastic agent used in oncology and hematology care. Nationally, accurate coding for injectable chemotherapy agents like treosulfan is critical for care coordination, claims processing, and payment integrity given high drug costs and site-of-service variability.
Key payers included in this overview are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare and Medicare. Readers will find a concise explanation of the code’s clinical purpose and typical sites of service, plus what to expect from payer coverage patterns and billing practice considerations. The publication outlines common modifier usage and operational elements for service line billing and claims submission when data is available.
This summary serves clinicians, billing professionals, and policy analysts seeking a national view of HCPCS Level II code J0614. It highlights the clinical context for treosulfan injections, where services are commonly delivered, and the kinds of benchmarks and policy topics that affect reimbursement and utilization oversight. Data not available in the input will be identified where relevant in subsequent sections.
Billing Code Overview
HCPCS Level II code J0614 represents an injection of treosulfan, 50 mg. This code denotes a pharmacologic therapy administration involving the cytotoxic agent treosulfan, typically used in oncology or hematology treatment regimens.
Service Type: Drug administration (injectable chemotherapy/antineoplastic agent)
Typical Site of Service: Hospital outpatient infusion center, outpatient oncology clinic, or ambulatory infusion center
Clinical & Coding Specifications
Clinical Context
A typical patient is an adult with recurrent or refractory ovarian cancer, malignant lymphoma, or myelodysplastic syndrome undergoing conditioning chemotherapy prior to autologous or allogeneic hematopoietic stem cell transplant. The patient presents to an oncology infusion center or hospital outpatient oncology clinic for administration of treosulfan (J0614, injection, 50 mg). Clinical workflow: pre-visit labs and organ function assessment (CBC, CMP, renal and hepatic panels), medication reconciliation, informed consent for high-dose chemotherapy, venous access verification (PICC, implanted port, or central venous catheter), antiemetic and supportive medications administered as indicated, weight-based dose calculation and pharmacy compounding of treosulfan per institutional protocol, bedside verification of dose and infusion orders, administration via intravenous infusion over the institution-specific duration, monitoring for acute infusion reactions, serial vital signs and laboratory monitoring during and after infusion, and documentation of dose, lot number, site, and any modifiers (e.g., JW for discarded drug) on the medication administration record and claim form. Typical site of service: hospital outpatient infusion center or inpatient oncology unit when administered as part of conditioning for transplant.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
JW |